Robert Doebele - 15 Feb 2023 Form 4 Insider Report for Rain Oncology Inc.

Role
President, Chief Scientific Officer
Signature
/s/ Nelson Cabatuan, Attorney-in-fact for Robert Doebele
Issuer symbol
N/A
Transactions as of
15 Feb 2023
Net transactions value
$0
Form type
4
Filing time
17 Feb 2023, 17:18:30 UTC
Previous filing
07 Jul 2022
Next filing
11 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RAIN Stock Option (Right to Buy) Award $0 +123,325 $0.000000 123,325 15 Feb 2023 Common Stock 123,325 $9.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase a total of 123,325 shares of the Issuer's common stock, one quarter of which will vest on February 15, 2024, with the remaining three quarters vesting in equal monthly installments through February 15, 2027, subject to the Reporting Person's continued service to the Issuer.

Remarks:

President, Chief Scientific Officer